Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week, randomized, multicenter, crossover study

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 4, 2015, Pages 141-148

  Lüdemann, Jörg ^a   Dütting, Eva D ^b   Dworak, Markus ^b  

^a Diabetes Medical Center   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

dipeptidyl peptidase 4 inhibitor; glucagon like peptide 1 analog; liraglutide; medication preference; type 2 diabetes mellitus; vildagliptin

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; VILDAGLIPTIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; PILOT STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 84938699899     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018815595584     Document Type: Article

References (13)

1. Bharmal M. Payne K. Atkinson M. Desrosiers M. Morisky D. Gemmen E. (2009) Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes 7: 36.
2. Charbonnel B. Steinberg H. Eymard E. Xu L. Thakkar P. Prabhu V. et al. (2013) Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 56: 1503–1511.
3. Dibonaventura M. Wagner J. Girman C. Brodovicz K. Zhang Q. Qiu Y. et al. (2010) Multinational internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication. Patient Prefer Adher 4: 397–406.
4. Hayes R. Bowman L. Monahan P. Marrero D. McHorney C. (2006) Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. Diabetes Educ 32: 404–414.
5. Inzucchi S. (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287: 360–372.
6. Ismail-Beigi I. Moghissi E. Tiktin M. Hirsch I. Inzucchi S. Genuth S. (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154: 554–9.
7. Keating G. (2014) Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 74: 587–610.
8. Khan K. Coyle F. Chowdhury T. (2009) Patients’ preference for subsequent therapy following secondary failure of metformin and sulphonylurea. Pract Diab Int 26: 282–284.
9. Novo Nordisk (2013) Liraglutide (Victoza®), 0.65 mg subcutaneous injection, prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [accessed 28 March 2015]
10. Pratley R. Nauck M. Bailey T. Montanya E. Cuddihy R. Filetti S. et al. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375: 1447–1456.
11. Scheen A. (2013) GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris) 74: 515–522.
12. Strain W. Lukashevich V. Kothny W. Hoellinger M. Paldánius P. (2013) Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 382: 409–416.
13. Sue K. Briscoe V. Clark N. Florez H. Haas L. Halter J. et al. (2012) Diabetes in older adults: a consensus report. J Am Geriatr Soc 60: 2342–2346.